At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Infliximab (Remicade) +1 moredrug
Likely dose
Infliximab (Remicade) 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy
In Brief
A Phase 1 clinical trial evaluating Infliximab (Remicade) and Intravenous immunoglobulin (IVIG) for Kawasaki Disease. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKawasaki Disease
CountriesUnited States
CollaboratorsCentocor, Inc.
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
First PostedJan 2006
Primary CompletionOct 2006
TodayJul 2026
First PostedJan 2, 2006
Enrollment StartApr 1, 2004
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.5 years ago
Interventions
Infliximab (Remicade)drug
Remicade was 5 mg/kg IV (single dose)
Intravenous immunoglobulin (IVIG)biological
2nd dose of IVIG (2g/kg)